Services enabled by this technology
Our locations
Drug product intermediates based on SDD technology can be formulated into capsules, tablets and other solid dosage forms. With our integrated product development approach, we can efficiently develop and manufacture SDDs and dosage forms for all stages of development and commercial-scale production:
The majority of today’s drug candidates have low aqueous solubility (BCS II) and require an enabling technology to enhance oral bioavailability. Amorphous solid dispersion approaches utilizing spray-dried dispersion (SDD) technology offer a proven and highly flexible approach to significantly improve the bioavailability of promising BCS ll compounds. Spray drying is also increasingly utilized for dry powder inhaler (DPI) applications, providing particle engineered formulations in the required particle size distribution to meet target product profiles.
With our integrated product development approach we can manufacture SDD formulations for all stages of development from preclinical and first-in-human to late-stage development and commercial production. Drug product intermediates based on SDD technology can be formulated into capsules, tablets and other solid dosage forms.
We have an approach of using spray-dried formulation that is revolutionary! Creating formulations that are targeted and appropriate
-Matthew Ferguson, Director Respiratory Delivery, R&D, Lonza Bend
SDD technology has been proven in thousands of compounds to result in significantly improved bioavailability, typically from three to 15-fold.
Design: the first step is understanding your problem statement and clearly defining the target product profile (TPP).
Develop: starting from the design and TPP, a team of experienced scientists and engineers develop the product using a proven roadmap approach. Generally, the formulations developed are “phase appropriate” to match the current development phase of the drug candidate.
Manufacture: we have a full range of pharmaceutical spray dryers, based on proprietary designs, to support early feasibility assessments through clinic studies and commercialization.
Associate Director, Respiratory Delivery